Tirzepatide in NASH: what the phase 3 trial data tells us

You've read that tirzepatide could help with liver disease — here's the context behind that

Suppose you or someone you know has been told they have NASH, or its newer diagnostic name MASH (metabolic dysfunction-associated steatohepatitis), and you've come across headlines suggesting tirzepatide might help. That's not wishful reading. The phase 3 SURMOUNT-NASH trial, results from which were published in the New England Journal of Medicine in 2024, set out to test exactly that question (in a rigorous, controlled setting) and the findings were significant enough to shift how liver specialists think about medical management of this condition.

NASH is not simply a fatty liver. It involves inflammation and cell damage alongside fat accumulation, and in a proportion of people progresses to fibrosis, cirrhosis and liver failure. Until recently, there were no approved drug treatments; lifestyle modification was the only intervention with good evidence. The interest in tirzepatide centres on its dual mechanism: it activates both GIP and GLP-1 receptors, influencing appetite, insulin sensitivity and, researchers believe, pathways that directly affect liver inflammation, not merely as a downstream effect of weight loss, but potentially through more direct routes. For a deeper look at the broader tirzepatide clinical evidence base, the tirzepatide phase 3 trial overview sets out what has been published across indications.

What the SURMOUNT-NASH phase 3 data actually showed

The trial enrolled adults with biopsy-confirmed NASH (fibrosis stages F2 or F3, meaning moderate to advanced scarring) and a BMI of 27 or above. Two co-primary endpoints were set: NASH resolution without worsening of fibrosis, and a reduction in fibrosis stage by at least one level without worsening of NASH activity. At 52 weeks, roughly 10% of participants in the placebo group achieved NASH resolution, a figure that reflects how difficult the condition is to reverse with lifestyle change alone. Among those receiving tirzepatide 10mg, the figure was around 51%; at 15mg, around 62%. Fibrosis improvement results followed a broadly similar direction.

These are striking numbers. They suggest tirzepatide's effect on liver histology goes well beyond what weight loss alone would predict, though separating the two in a trial where participants also lose substantial body weight is methodologically complex. Lilly has described the SURMOUNT-NASH results as supportive of a regulatory submission, and the trial has been reported on extensively in hepatology circles. For a closer reading of the liver-specific trial programme, the tirzepatide and NASH evidence page covers the detail, and the SYNERGY-NASH trial explores a related investigation using a different comparator. The NEJM publication remains the primary source for the histological outcome data.

What this means in practical UK terms right now

Tirzepatide in the UK (sold as Mounjaro) is licensed for weight management and type 2 diabetes. It is not currently licensed specifically for NASH or MASH in the UK, which means it cannot be prescribed for liver disease through a routine route. That may change: Eli Lilly has been progressing regulatory submissions in multiple markets, and the UK's MHRA will evaluate any application independently. The situation is not unlike where semaglutide stood before its July 2026 MHRA conditional approval to treat MASH, a regulatory milestone that illustrates the direction of travel for GLP-1 medicines in liver disease.

For people who have NASH alongside obesity or type 2 diabetes, the picture is more nuanced. A prescriber can consider tirzepatide for those licensed indications, and if liver benefit follows, that is consistent with the evidence, but the prescription is made on the licensed basis, not as a NASH treatment. The UK Mounjaro pricing context is worth understanding if cost is a factor in your thinking. The broader tirzepatide overview explains the medicine's licensed use, eligibility criteria and how a private prescription works in practice. Any conversation about liver disease specifically belongs with a hepatologist or a GP who knows your full clinical picture, a prescriber deciding on tirzepatide for weight management will also need to know about any liver condition you've been diagnosed with.

What to do if you're exploring tirzepatide for weight management and have a liver condition

Liver disease doesn't automatically exclude someone from tirzepatide, a clinician needs to assess the type and severity of the condition alongside everything else. NASH at early fibrosis stages, for example, is different from advanced cirrhosis. The prescribing process for any GLP-1 medicine involves a thorough clinical review; at nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day it's submitted. That review takes into account co-existing conditions, current medicines and any safety considerations the standard POM eligibility criteria might not explicitly list. If you're thinking about it and you have a GP appointment already in your calendar (perhaps before the school run tomorrow) it's worth raising the liver question there too, even if you're planning to go through a private pharmacy.

The weight-loss treatment options page sets out what's available through nume, and our clinical team overview explains the governance behind every prescription decision. If you have questions before starting, our FAQs cover the most common ones; for anything more specific, the contact page connects you directly with the team. When you're ready to proceed, checking your eligibility takes a few minutes and costs nothing.